CoChat

Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies

Open access

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 1 of the 6 sources its claims cite were checked for support.

Abstract

Systematic review and meta-analysis of observational studies was conducted in PubMed, Embase, and Web of Science from 2006 to 2025. 28 observational studies (6 for semaglutide and 22 for all GLP-1 RAs) involving T2DM patients were included. When compared to other antidiabetic treatments, GLP-1 RAs did not increase the risk of developing ocular disorders such as NAION (RR, 1.01; 95% CI, 0.62-1.64; I2, 89%), glaucoma (HR, 0.84; 95% CI, 0.71-1.00; I2, 91%), and retinopathy (HR, 0.96; 95% CI, 0.85-1.08). Even if no difference was observed, it is optimal to monitor the administration of these molecules.

Overview

CoChat Summary

## TL;DR

This systematic review and meta-analysis of 28 observational studies found no statistically significant increase in ocular adverse events with GLP-1 receptor agonists versus other antidiabetic drugs for NAION, glaucoma, or diabetic retinopathy. The authors still recommend monitoring, because the evidence showed high heterogeneity and some outcomes were driven by only a few studies.

## Key findings

  • The review included 28 observational studies: 6 single-arm studies and 22 double-/three-arm studies, all in T2DM patients.
  • In the overall analysis, GLP-1 RAs did not increase risk of NAION: RR 1.01 (95% CI 0.62–1.64; I² = 89%).
  • GLP-1 RAs did not increase risk of glaucoma relative to non-GLP-1 comparators: HR 0.84 (95% CI 0.71–1.00; I² = 91%).
  • GLP-1 RAs did not increase risk of new-onset diabetic retinopathy: HR 0.96 (95% CI 0.85–1.08; I² = 91%), and did not increase risk of retinopathy progression: HR 0.97 (95% CI 0.83–1.14; I² = 65%).
  • In single-arm studies, the pooled prevalence of ocular adverse events was 2% (95% CI 0.01–0.03), and the pooled prevalence of diabetic retinopathy was 4% (95% CI 0.01–0.08).

## Methods

  • Design: PRISMA-guided systematic review and random-effects meta-analysis of observational studies, registered in PROSPERO (CRD420251080120).
  • Data/sample: Searches of PubMed, Embase, and Web of Science from 1 January 2006 to 7 March 2025 identified 5,713 articles; 28 observational studies met inclusion criteria. Included populations had T2DM and/or overweight/obesity and used GLP-1 RAs such as semaglutide, dulaglutide, liraglutide, lixisenatide, exenatide, or tirzepatide.
  • Main analysis: Random-effects meta-analysis of ocular outcomes (NAION, glaucoma, new-onset DR, DR progression); heterogeneity was assessed with Q and I², publication bias with funnel plots when possible, and leave-one-out sensitivity analyses were performed.

## Limitations

  • The paper explicitly states that the meta-analysis is limited by substantial heterogeneity, different study characteristics (sample size, geography, follow-up), limited subgroup data, and possible confounding from concomitant antidiabetic therapies.
  • The paper also states that many studies lacked detailed clinical/biochemical data or disease severity information, and that some outcomes, especially NAION, were based on few studies, making estimates less robust.
  • Evident from the text: because nearly all included studies were observational and many were retrospective, the results are vulnerable to confounding and selection bias.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fphar.2026.1808359

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 Flow chart illustrating the literature search outcomes.
FIGURE 1 Flow chart illustrating the literature search outcomes.CC BY · PubMed Central
FIGURE 2 Proportion of ocular adverse events among patients receiving GLP-1 RAs in observational studies.
FIGURE 2 Proportion of ocular adverse events among patients receiving GLP-1 RAs in observational studies.CC BY · PubMed Central
FIGURE 3 Proportion of diabetic retinopathy among patients receiving GLP-1 RAs in observational studies.
FIGURE 3 Proportion of diabetic retinopathy among patients receiving GLP-1 RAs in observational studies.CC BY · PubMed Central
FIGURE 4 Risk of diabetic retinopathy for GLP-1 RAs compared to that for other antidiabetic drugs (LAI, TZD, SGLT2-i, metformin, and DPP4-i). Wang (2018): GLP-1 RAs vs. TZD. Wang et al. (2018)*: GLP-1 RAs vs. LAI. Eleftheriadou et al. (2024): GLP-1 RAs + insulin vs. control (insulin with no GLP-1 RAs). Eleftheriadou et al. (2024)*: GLP-1 RAs + insulin vs. SGLT2-i + insulin. Yen et al. (2024): GLP-1 RAs vs. DPP4-i. Yen et al. (2024)*: GLP-1 RAs vs. SGLT2-i. Yen et al. (2024)**: GLP-1 RAs vs. SU.
FIGURE 4 Risk of diabetic retinopathy for GLP-1 RAs compared to that for other antidiabetic drugs (LAI, TZD, SGLT2-i, metformin, and DPP4-i). Wang (2018): GLP-1 RAs vs. TZD. Wang et al. (2018)*: GLP-1 RAs vs. LAI. Eleftheriadou et al. (2024): GLP-1 RAs + insulin vs. control (insulin with no GLP-1 RAs). Eleftheriadou et al. (2024)*: GLP-1 RAs + insulin vs. SGLT2-i + insulin. Yen et al. (2024): GLP-1 RAs vs. DPP4-i. Yen et al. (2024)*: GLP-1 RAs vs. SGLT2-i. Yen et al. (2024)**: GLP-1 RAs vs. SU.CC BY · PubMed Central
FIGURE 5 Risk of progression of diabetic retinopathy for GLP-1 RAs compared to that for other antidiabetic drugs (LAI, TZD, and SGLT2-i). Wang et al. (2018): GLP-1 RAs vs. TZD. Tauqeer (2024): outcome: progression of DR. Tauqeer et al. (2025)*: outcome: vision-threatening DR.
FIGURE 5 Risk of progression of diabetic retinopathy for GLP-1 RAs compared to that for other antidiabetic drugs (LAI, TZD, and SGLT2-i). Wang et al. (2018): GLP-1 RAs vs. TZD. Tauqeer (2024): outcome: progression of DR. Tauqeer et al. (2025)*: outcome: vision-threatening DR.CC BY · PubMed Central
FIGURE 6 Risk of glaucoma for GLP-1 RAs compared to that for other antidiabetic drugs (SGLT2-i, DPP4-i, metformin, an insulin). Allan (2025): GLP-1 RAs vs. metformin. Allan et al. (2025)*: GLP-1 RAs vs. insulin.
FIGURE 6 Risk of glaucoma for GLP-1 RAs compared to that for other antidiabetic drugs (SGLT2-i, DPP4-i, metformin, an insulin). Allan (2025): GLP-1 RAs vs. metformin. Allan et al. (2025)*: GLP-1 RAs vs. insulin.CC BY · PubMed Central
FIGURE 7 Risk of NAION for semaglutide compared to that for other antidiabetic drugs (SGLT2-i, glipizide, empagliflozin, and sitagliptin). Cai et al. (2025): GLP-1 RAs vs. sitagliptin. Cai et al. (2025)*: GLP-1 RAs vs. glipizide. Cai et al. (2025)**: GLP-1 RAs vs. empagliflozin.
FIGURE 7 Risk of NAION for semaglutide compared to that for other antidiabetic drugs (SGLT2-i, glipizide, empagliflozin, and sitagliptin). Cai et al. (2025): GLP-1 RAs vs. sitagliptin. Cai et al. (2025)*: GLP-1 RAs vs. glipizide. Cai et al. (2025)**: GLP-1 RAs vs. empagliflozin.CC BY · PubMed Central
FIGURE 8 Leave-one-out sensitivity analysis for the outcome NAION.
FIGURE 8 Leave-one-out sensitivity analysis for the outcome NAION.CC BY · PubMed Central

Verification

Claims the paper makes

1 Valid · 0 Not valid · 2 Not checked · 20 Own results and interpretations

6 more claims

Create a free account to see all 23 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 7
  • It may state two separate claims as one. 5

Create a free account to see these claims.

Citations

Cites

Show all 77 references

Research works printed but not linked: 5

  1. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines ozempic, Rybelsus Wegovy
  2. Summary of Product Characteristics (Saxenda)
  3. Summary of Product Characteristics (Wegovy)
  4. Summary of Product Characteristics (Mounjaro)
  5. International Diabetes Federation. IDF Diabetes Atlas, 2021, IDF Diabetes Atlas

Metadata

Authors
Anatriello, A., Liguori, V., Cagnotta, C., Pentella, C., Scavone, C., Capuano, A., & Rinaldi, B.
Affiliations
University of Campania "Luigi Vanvitelli" (IT)
Corresponding author
Liguori, Valerio
Venue
Frontiers in pharmacology
Published
2026-06-02
Volume
17
Pages
1808359-1808359
ISSN
1663-9812 (ISSN-L)
OpenAlex
W7163212561
Cited by
3
References
73
Citations by year
2026: 3
FWCI
3.18
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
GLP-1 receptor agonists, ocular adverse effects, retinopathy, glaucoma, nonarteritic anterior ischemic optic neuropathy, semaglutide, type 2 diabetes, drug safety, antidiabetic drugs, obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies. https://app.cochat.ai/papers/10.3389/fphar.2026.1808359
The paper
Anatriello, A., Liguori, V., Cagnotta, C., Pentella, C., Scavone, C., Capuano, A., & Rinaldi, B. (2026). Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1808359

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.